Indication

Lialda is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.

Important Safety Information

Read More Below

Indication

Lialda is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.

Important Safety Information

  • Lialda is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of Lialda.
  • Renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported with products such as Lialda that contain mesalamine or are converted to mesalamine. It is recommended that patients have an evaluation of renal function prior to initiating use of Lialda and periodically while on therapy. Exercise caution when using Lialda in patients with known renal dysfunction or a history of renal disease.
Read more
 
 

Covered for more than 90% of total Commercialand Medicare Part D patients nationwide.2*

*"Coverage" means covered at any tier without restrictions.

"Commercial" includes commercial plans, PBMs, employers, and unions.

Find coverage in your area.

 
 

#1 PRESCRIBED 5-ASA Among Gastroentrerologists1

Your patients have access to support programs & materials.

Lialda Resources - On Call

Call 1-800-828-2845
to request samples and get real-time answers on patient coverage and support.

Learn more